PANK1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL18997651	0.42	5/20
SCHEMBL2491262	0.55	2/20
SCHEMBL19381945	0.38	2/20
SCHEMBL19382001	0.38	2/20
SCHEMBL1869690	0.52	1/20
SCHEMBL18703526	0.52	1/20
SCHEMBL18712002	0.51	1/20
SCHEMBL23156598	0.50	1/20
SCHEMBL24823218	0.48	1/20
SCHEMBL18711570	0.47	1/20
SCHEMBL27405989	0.47	1/20
SCHEMBL26502798	0.47	1/20
SCHEMBL13993858	0.47	1/20
SCHEMBL17620345	0.46	1/20
SCHEMBL4409427	0.46	1/20
SCHEMBL7018465	0.46	1/20
SCHEMBL26158261	0.45	1/20
SCHEMBL2825133	0.45	1/20
SCHEMBL6211798	0.44	1/20
SCHEMBL17620310	0.44	1/20

Clinical trials — most relevant to PANK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes	PHASE4	COMPLETED
Acelarin First Line Randomised Pancreatic Study	PHASE2/PHASE3	SUSPENDED
Study of BKM120 in Advanced Squamous Cell Carcinoma of Head and Neck	PHASE2	UNKNOWN
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients	PHASE2	COMPLETED
Biological Effects of Quercetin in COPD	PHASE1/PHASE2	UNKNOWN
Biological Effects of Quercetin in COPD Phase II	PHASE2	UNKNOWN
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
Safety and Feasibility of Metformin for Sepsis Induced AKI	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer	PHASE2	COMPLETED
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer	PHASE1/PHASE2	COMPLETED
Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults	PHASE1	RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer	PHASE1	ACTIVE_NOT_RECRUITING
Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors	PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression	nan	COMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas	nan	RECRUITING
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms	nan	RECRUITING
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
Pancreatic Intraepithelial Neoplasia (PanIN) and the Association With Recurrence of Pancreatic Adenocarcinoma	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Tumor Kinase Inhibitor Concentrations Measured by PET	nan	COMPLETED
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PANK1 binder may also engage these)

Protein	Name	Similarity
Q8K4K6	—	0.998	Q8K4K6 →
D3YWQ0	—	0.995	D3YWQ0 →
PANK2	Pantothenate kinase 2, mitochondrial	0.994	landscape →
F1MAB7	—	0.992	F1MAB7 →
Q5TKR9	—	0.991	Q5TKR9 →
Q8K3A9	—	0.990	Q8K3A9 →
DGKI	Diacylglycerol kinase iota	0.990	landscape →
Q8TBC3	—	0.990	Q8TBC3 →
Q9UPV7	—	0.989	Q9UPV7 →
Q8BWQ5	—	0.989	Q8BWQ5 →
Q8BJM7	—	0.989	Q8BJM7 →
Q63553	—	0.989	Q63553 →
A3KMV1	—	0.988	A3KMV1 →
KDM4B	Lysine-specific demethylase 4B	0.988	landscape →
Q9BQI7	—	0.988	Q9BQI7 →
RXRB	Retinoic acid receptor RXR-beta	0.988	landscape →
MCL1	Induced myeloid leukemia cell differentiation protein Mcl-1	0.988	landscape →
Q8BMD7	—	0.988	Q8BMD7 →
Q8HYS5	—	0.988	Q8HYS5 →
Q28314	—	0.988	Q28314 →
KAT8	Histone acetyltransferase KAT8	0.988	landscape →
SIRT1	NAD-dependent protein deacetylase sirtuin-1	0.988	landscape →
Q8BV79	—	0.988	Q8BV79 →
Q60700	—	0.988	Q60700 →
O95343	—	0.988	O95343 →
Q2PFD7	—	0.987	Q2PFD7 →
Q9BQK8	—	0.987	Q9BQK8 →
Q17QK1	—	0.987	Q17QK1 →
Q6P1I6	—	0.987	Q6P1I6 →
Q99PI5	—	0.987	Q99PI5 →